(Q41109684)

26 September 2017

1 reference

title

Therapy of chronic viral hepatitis (English)

1 reference

26 September 2017

Fried MW

1

1 reference

26 September 2017

1 September 1996

1 reference

Medical Clinics of North America

26 September 2017

1 reference

26 September 2017

80

1 reference

26 September 2017

957-972

1 reference

26 September 2017

5

1 reference

Interferon-α increases prostaglandin E2 production by cultured liver biopsy in patients with chronic viral hepatitis: can non-steroidal anti-inflammatory drugs improve the therapeutic response to interferon?

26 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

A preliminary trial of lamivudine for chronic hepatitis B infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Therapy of chronic hepatitis B with a 6-month course of ribavirin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

7 January 2021

Therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

A pilot study of 2',3'-dideoxyinosine for the treatment of chronic hepatitis B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB/C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

HCV genotypes in chronic hepatitis C and response to interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Long-term remission of chronic hepatitis B after alpha-interferon therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Genotypic analysis of hepatitis C virus in American patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Hepatitis C virus infection in patients with essential mixed cryoglobulinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Molecular therapeutic strategies in hepatitis B virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Mechanisms of action of interferons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Side effects of alpha interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Psychiatric complications of long-term interferon alfa therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Decrease in Serum Hepatitis C Viral RNA during Alpha-Interferon Therapy for Chronic Hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Long-term follow-up of patients with chronic hepatitis C treated with α-interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Risk factors for hepatocellular carcinoma among patients with chronic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Response to interferon alpha therapy is influenced by the iron content of the liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Clinical aspects of hepatitis B virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970475-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-7125(05)70475-2

1 reference

26 September 2017

1 reference

PubMed ID

8804370